Is Kymera Therapeutics, Inc. (NASDAQ:KYMR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kymera Therapeutics, Inc. at current levels.
An oral pill that mimics Dupixent could rewrite a $20B immunology market, and Kymera owns the lead molecule.
Where KYMR is headed
Kymera is two years away from being the company that broke the injectable monopoly in TH2 inflammation. KT-621 is an oral pill that degrades STAT6, the transcription factor that sits downstream of IL-4 and IL-13. Translation for the wallet: it does what Dupixent does, in a tablet, taken daily, with the potential to address the 80% of atopic dermatitis, asthma, and EoE patients who never agreed to inject themselves twice a month. Dupixent did $14 billion in 2025 with one hand tied behind its back because of the needle. Remove the needle, and the market doubles. Maybe triples.
Read the full Compass Direction on KYMR
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $86.20).
See the full KYMR analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Kymera Therapeutics, Inc. (NASDAQ:KYMR) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kymera Therapeutics, Inc. at current levels. An oral pill that mimics Dupixent could rewrite a $20B immunology market, and Kymera owns the lead molecule.
What is KYMR's Compass Score?
Kymera Therapeutics, Inc. scores 79/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for KYMR?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the KYMR page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.